Bio-Modeling Systems
The Mechanisms-Based Medicine Company

Everything you always wanted to know about Digital Health revolution “big promises” but were afraid to ask!

Or, why we invented CADI Discovery in 2004
Computer Augmented Intelligence Rational

This is not a pitch presentation
This document is for download only
We added the necessary details and explanations in the slides to help the reader

Conference INSEAD Alumni at BCG Paris Office July 4, 2017
updated April 2019
Manuel GEA : CEO, Co-founder, VP IT R&D
manuel.gea@bmsystems.net
What type of Systems are we talking about?

Complicated Systems

Complex Systems

Two systems with completely different behaviors
The biggest is not necessarily the most complex!
The nightmare of new mums.

The mission: build a model to simulate the behavior of spaghettis to prevent spots

The right question is: how does she protect clothes from spaghetti sauce?

The discovery of the BIB concept by Mum: A non-cartesian discovery but a Cartesian production process
The Life-modeling issue illustrated

1- If you dream of creating the first operational model of a bird...

2- ... a “basic” living Complex System that not only flies...

3- Be sure to use the appropriate modeling concepts & tools. If you don’t...

4- ... you’ll get a Complicated “Cartesian” system. It flies... But the major issue is that, for modelers, this is a bird!*

The challenge is clearly not a question of technologies only! Even with expensive efforts, this model will never become a “bird”!

* Based on this model, 1) when birds lay eggs, they explode; 2) the rear end of a bird is extremely hot when it flies; 3) a bird has three legs, etc.... You may think this stupid, but it is what is being done with systems biology.
“Reductionism” creates clear misunderstanding

Initially 1 billions € to simulate the complete human brain on supercomputers simulating neurons to better understand how it functions
The program did not delivered and was dramatically reduced:

But the brain Complex, the program failed to deliver due to its founders exaggerated ambition
Because the brain can’t be reduced to its neurons only!

The word “Deep” learning refers to the number of layers only!!!
The long AI History: What’s next step

AI has a long history of being “The next big thing”...

Timeline of AI Development

- **1950s-1960s**: First AI boom - the age of reasoning, prototype AI developed
- **1970s**: AI winter I
- **1980s-1990s**: Second AI boom: the age of knowledge representation (appearance of expert systems capable of reproducing human decision-making)
- **1990s**: AI winter II
- **1997**: Deep Blue beats Gary Kasparov
- **2006**: University of Toronto develops Deep Learning
- **2011**: IBM’s Watson wins Jeopardy
- **2016**: Go software based on Deep Learning beats world’s champions

Source: https://www.actuaries.digital/2018/09/05/history-of-ai-winters/
The IA and Big Data Giants do not deliver their promises

For The latest and cumulative alerts

Google’s Health Moonshot Comes Back to Earth: Verily Life Sciences is beginning a four-year health-tracking study that likely costs eight figures. *Bloomberg April, 19, 2017*

*By Caroline Chen and Mark Bergen*

Latest news: IBM halting sales of Watson AI tool for drug discovery amid sluggish growth says *STATNews*

How IBM Watson Overpromised and Underdelivered on AI Health Care says *IEEE Spectrum!*

IBM Has a Watson Dilemma. Big Blue promised its AI platform would be a big step forward in treating cancer. But after pouring billions into the project, the diagnosis is gloomy. *The Aug. 11, 2018 12:19 a.m.*

MD Anderson Drops IBM Watson – A Setback For Artificial Intelligence In Medicine?

AI alert: "IBM’s Watson supercomputer recommended ‘unsafe and incorrect’ cancer treatments" reveal *StatNews* & WSJ Forbes

And, the real IA professionals and regulators start to move

"L'intelligence artificielle a moins de sens commun qu'un rat" Yann Le Cun Dir. Facebook AI Research dans une interview vérité "Ce qui manque aux machines [pour dépasser l'homme], c'est l'intelligence générale"

“Artificial Intelligence does not exist” says Luc Julia the Innovation VP Samung (2019). What is called generalized AI does not exist and with current techniques it will never exist. What is called weak AI is the artificial intelligence of today, it is what we do with automatic learning, deep learning and has nothing to do with intelligence.

"La robustesse de la décision et l'explicabilité de la prise de décision algorithmique devront être garanties. La HAS favorable à l’adoption de normes de développement des algorithmes en santé."

Visit our Post on linkedin https://www.linkedin.com/pulse/ibms-watson-supercomputer-recommended-unsafe-cancer-manuel-gea-/
Digital Health: uncontrolled marketing vs reality?
## The 2 visions of the world: Holism - Reductionism

<table>
<thead>
<tr>
<th>Holism</th>
<th>Reductionism</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. Systems Biology</td>
<td>2. Bioinformatics</td>
</tr>
<tr>
<td>3. General Semantics</td>
<td>3. Cartesianism</td>
</tr>
<tr>
<td>5. &quot;Mechanisms-based Medicine&quot;</td>
<td>5. Evidence-Based Medicine</td>
</tr>
<tr>
<td>6. Human Intelligence</td>
<td>6. Artificial intelligence</td>
</tr>
<tr>
<td>7. Descriptive modeling</td>
<td>7. Mathematical simulation</td>
</tr>
<tr>
<td>8. Complete natural products</td>
<td>8. Pure active ingredient</td>
</tr>
<tr>
<td>10. Sociology, Mechanisms of the living, The nature that surrounds us</td>
<td>10. All the products created by the man the world we built</td>
</tr>
</tbody>
</table>

The objective should be to take the best of the two paradigms
# The Differences of “Internet” and “Life sciences” worlds

<table>
<thead>
<tr>
<th>Founding basements of the “big data” successes of the digital giants built for “the internet” world:</th>
<th>Founding basements of Life Sciences R&amp;D that may explain the so far unsuccessful attempts.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. The internet world built by humans is only very complicated not complex!</td>
<td>1. Life’s mechanisms are complex and clearly not well described.</td>
</tr>
<tr>
<td>2. Personal data producers do not” know” what these digital giants do with their “big data”.</td>
<td>2. Personal data producers are still not aware of their data usages and their business value.</td>
</tr>
<tr>
<td>3. Professional data producers do not have a real incentive to lie!</td>
<td>3. Professional data producers globally have a strong incentive to lie due to the “publish or perish” dilemma.</td>
</tr>
<tr>
<td>4. Algorithm’s recommendations based on rules do not need to be fully validated because there is no vital consequence for the user.</td>
<td>4. Algorithms which MUST follow rules are unable to address a complex world where humans do not follow them.</td>
</tr>
<tr>
<td>5. Correlations found by &quot;Big Data&quot; Scientists are useful to optimize &quot;personalized&quot; marketing and business outputs.</td>
<td>5. Correlations generated by the Data Scientists are misleading and do not make the differences between causes and consequences of the diseases, which is the real issue.</td>
</tr>
<tr>
<td>6. The regulators are aware of the use of the data but the consequences are still limited in the short term.</td>
<td>6. The regulators are fully aware of the risks and possible irreversible consequences for patients (insurance issue, wrong diagnostic …)</td>
</tr>
</tbody>
</table>

The founding basements of the two worlds do not obey the same rules.
The 3 dimensions to describe the system type

The objective is to use and combine the right concepts and tools adapted to the nature of the problem (such as heuristic modeling / mathematical modeling)
The Future of Life Sciences & Medicine

Google, Watson, etc... with their Artificial Intelligence

OR

Smart MDs, Biologists, Physiologists, nurses, other Healthcare professionals educating and mastering them

CADI Discovery: Computer Augmented Deductive Intelligence
The best collaboration between the two “complementary intelligences”
The Artificial vs Augmented Intelligence Story

Artificial “Non Human” Intelligence

Artificial “Human” Intelligence

Invasive “Augmented” Human Intelligence

Ex: CADI™ Discovery

What should be the most productive collaboration?
CADI Discovery belongs to the Non-invasive “Augmented” Human Intelligence concepts
The smart Collaboration Artificial - Augmented Intelligence

“The Singularity”  
Artificial “Human” Intelligence

Complicated Systems world  
Artificial “Non Human” Intelligence

Complex Systems world  
Non-invasive “Augmented Human Intelligence

“Transhumanism”  
Invasive “Augmented” Human Intelligence

Artificial “Intelligence”  
“Augmented” Human Intelligence

“The smart collaboration”  
Ex: CADI™ Discovery

The smart collaboration in the right order
CADI Discovery belongs to the Non-invasive “Augmented” Human Intelligence concepts

© BMSystems 2017 - www.bmsystems.net
Why did we need to change the discovery paradigm?

1- The industry is under high pressure by too high failure rates (90%-95%) and payers no more willing to pay premium therapies with very limited patient benefit.

2- The limits of the big Pharma model. Decades of investments in Omics technologies and Systems Biology programs produced few relevant results due to 3 “side effects” and a conceptual mistake: Life mechanisms are complex not complicated!

3- The “mirage” of Artificial Intelligence (AI) that MUST follow rules in a world where humans massively do not! Currently the “Garbage in garbage out” reality is not correctly treated by digital giants who consider life as only complicated.

4- The unreliability of scientific and clinical publications is increasing. “Many published research findings are false or exaggerated; an estimated 85% of research resources are wasted.” (Stanford university), and the valuable negative results are not published.

So why despite massive investments in technology and IT, the success rate of the industry is still declining? The challenge is not a question of technologies only!
The limits of the Pharma drug discovery process

With a 90%-95% failure rate this Big Pharma R&D model focused on testing new patentable compounds for novel targets based on KOL concepts is not performant!

1. Is 1 billion € per drug approved a fatality or a Discovery paradigm failure?
2. How are KOL concepts generated and evaluated?
3. Has Evidence based Medicine reached its limits with chronic complex human diseases?
4. Mechanisms of action/function of a target, drug, gene, .. ARE NOT the mechanisms of a complex disease / disorder
5. Are the data produced and the scientific publications reliable and robust enough to feed algorithms that MUST follow rules?

Understanding and validating the mechanisms of a disease/disorder becomes the first objective.
Finding the most adapted solutions is a necessary consequence of the first objective.
The 3 major “side effects” of the discovery of molecular biology, and the endless Omics story that began in the 70’s

1. Medical research focused on patient’s diseases became life sciences research driven by data, technologies and IT outputs.
2. The leadership switched from MDs & biologists to molecular & IT scientists.
3. The discovery issue: Tools, algorithms & concepts from Digital and Technologies giants, valid for complicated systems, cannot address complex systems such as life.

© BMSystems - www.bmsystems.net
Floods of heterogeneous data exponential growth

« And that’s why we need a computer. »

Integrative biology became “bio-informatics”
The new Eldorado for IT and technology sellers
IT, HPC, Big Data ..... Big knowledge or big Garbage?
What leads to Therapeutic Success?

The success of a therapeutic approach largely arises from the coherent manipulation of a physiological system as a whole and not from that of a target in a molecular context.

Therefore, any given medical problem should be approached from a “systems medicine” standpoint.

In this context, novel therapies can be combinations of drugs, nutriments, devices, e-health, etc.….while targeted therapies belong to the “target in a molecular context” concept

Do not forget: Mechanisms of action or function of a target, drug, gene, etc. ARE NOT the mechanisms of a complex disease / disorder
The life mechanisms reality
From genes to physiological functions:

Four series of deconvolutions and discontinuities:

*At each step, the alternative options are context-dependent AND cannot be directly predicted*

One gene = several different physiological functions

A non-linear integrative system.

At each step, the alternative options are context-dependent AND cannot be directly predicted.

25 000 genes for more than 1 000 000 proteins functions.

DNA alone cannot explain life functions

© BMSystems 2017 - www.bmsystems.net

*Complex: is a group of two or more associated proteins or peptides*
Complex Problems Solving with a simple example

Problème
Complex Problems Solving with a simple example

The power of “General Semantic” to address complexity
If you don’t understand “Data Scientists”, maybe you are right!
Think and do out of the box!
The Global Health dilemma

Evidence-Based Medicine

Real life Medicine

90,4% failure rate! And “usages” that still need to prove their long run ROI Cartesian solutions for Complex Systems issues can improve?
What leads to Therapeutic Success?

The success of a therapeutic approach and not from that of a target in a molecular context.

Therefore, any given medical problem should be approached from a “systems medicine” standpoint.
The Holy Grail of the Healthcare industry
From bench to bed to real patient health processes

Information technologies
Data acquisition, Simulation, collaborative, data Storage, Big Data, Smart Data, Mobility
Smart Data (contextualized, with patients based lines, related to mechanisms)
The Research & Development Answer

Evidence-Based Medicine

Mechanisms-Based Medicine

1-DISEASE/DISORDER
2-MECHANISMS
3-BIOMARKERS
4-TARGETS
5-SOLUTIONS
6-VALIDATION

90.4% failure rate!
The “Cartesian” answers limits

The “garbage in, garbage out” reality demonstrates that a wrong hypothesis, even if generated by top KOLs and/or treated by the best Digital and IT technologies, remain a wrong hypothesis.

CADI Discovery Principles

1. Mechanisms-Based Medicine
2. Architectural Principle
3. Negative Selection Principle
4. 4 Steps Validation Principle
5. Integrated Solutions Principle
6. The bridge R&D & Real life data
The mechanisms-Based Medicine Principles

The Global Discovery stepwise approach places diagnostic / therapies / prevention solutions & validation processes in the right order:

“1-DISEASE”
- Redefine the definitions and descriptions of the physiopathology of the disease/disorder/syndrome with physiologists, clinicians and patients feedbacks.

“2-MECHANISMS”
- Discover the causal versus symptomatic mechanisms of the disease/disorder
- Mechanisms of action or function of a target, gene, etc. ARE NOT the mechanisms of a complex disease / disorder. It is the same with the mechanisms of action for drugs.

“3-BIOMARKERS”
- Indirectly based on causal mechanisms, identify relevant biomarkers or specific biomarkers combination/signatures (biological, imagery, physical signals, etc....) that could measure defined mechanistic deregulations at different stages of disease/disorder progression.

“4-TARGETS”
- based on the causal mechanisms, identify what could be the best targets (not only one) to specifically address the causative deregulations.

“5-SOLUTIONS”
- We harness the mechanisms to propose the most practical solutions addressing the relevant mechanistic deregulations.
- It is important to notice that the proposed solutions, integrating diagnostics, therapies & patients follow-up, can be new drugs, combinations of existing drugs, nutriments, devices, e-health, disease prevention tools and services, etc.
- Global validation loop at each steps of the process: Integrate the results from e-R&D or e-Health experimentations into the validation process to improve global patient and disease/disorder follow-up.

“6-VALIDATION”
- The mechanisms-Based Medicine Principles

© BMSystems - www.bmsystems.net

*Computer Augmented Deductive Intelligence*
The unreliability of scientific and clinical publications is unacceptable and increasing

- **85%** of research resources are *wasted*. Currently, *many published research findings are false or exaggerated* (John P. A. Ioannidis METRICS Institute Stanford University. Published in Plos medicine 2014)

- **90%** of 53 studies were not reproducible. Amgen’s scientists couldn’t reproduce the findings of 53 “landmark” articles in cancer research (C. Glenn Begley ex Amgen. Published in Nature, 2012)

- **79%** of 67 projects were not reproduced by Bayer’s scientists trying to reproduce the findings of 67 target-validation projects in oncology, women’s health, and cardiovascular medicine. (Florian Prinz, Thomas Schlange and Khusru Asadullah Reu Bayer. Published in Nature discovery 2011)

The “garbage in, garbage out” reality demonstrates that a wrong hypothesis, even if generated or treated by the best Digital and IT technologies, remains a wrong hypothesis.

Ferric C. Fang et al. PNAS 2012;109:17028-17033
Publications do not represent the real knowledge especially when the results are negative

Based on 74 antidepressant clinical trials submitted to FDA for approval

![Bar Chart]

- Positive Results: 38 trials, 37 published
- Negative & Questionable Results: 36 trials, 3 published

Publications do not represent the real knowledge especially when the results are negative.

Based on 74 antidepressant clinical trials submitted to FDA for approval.

An enormous bias. A critically misleading issue if not contextualized.

CADI*™ Discovery Principles

“Mechanisms-Based Medicine Principle”
- Answers the failures of the pharma Research Process & of the “KOL dominant thinking” by fostering the discovery & selection of novel concepts.
- Need to separate causal mechanisms understanding from solutions discovery.
- Discovery of lower risk & cost effective multi-technologies and integrated solutions.

“Architectural Principle”
- Mechanisms of life are complex, non-linear and integrative.
- Heuristic Modeling (the Architects) searches for satisfactory solutions to describe the mechanism of a poorly defined system.
- Mathematical Modeling (the Engineers) simulates, when correctly described, the dynamics of the system.

“Negative Selection Principle”
- “It is always possible to demonstrate a statement to be false” Karl Popper.1963.
- Despite the accumulation of evidence, such as Stanford University with METRICS institute, that 85% research results are false/exaggerated/useless, there still is extractable value.
- We eliminate what is impossible (“Negative Selection Process”), what remains may not be true but must be taken into consideration.

“4 Steps Validation Principle”
- Only mechanisms that resisted the “Negative Selection Process” are worth testing.
- Iterative validation process with the necessary scientists, clinicians, MDs, and patients.
- Construction of dedicated experimentations to evaluate the predictions of the model.
- Necessary bridge between R&D, clinic and real life.

“Integrated Solutions Principle”
- Can be combinations of drugs, diagnostics, medical devices, nutriments, e-health, cosmetics, for treatments, and prevention programs, etc. ...
- Access to end user is strategic, and digital technologies are essentials to connect all the components of the solutions.

CADI™ Discovery is the world’s first and, to date, only operational platform combining the strengths of human and artificial intelligences in the right order.
Mathematical & Heuristic approaches can be complementary, provided they are harnessed in the proper order.

Mathematical approaches are of limited usefulness when applied to poorly defined multicellular physiological systems because they cannot efficiently reveal & define the functional states within such a system (cross-talks alterations, etc...).

But heuristic approaches are very efficient at doing precisely this.

Heuristic models are of limited usefulness when addressing the dynamics of defined complex physiological pathways structures and cross-talks because they are not open to mathematical manipulations.

But Mathematical models are very efficient at doing precisely this.

To efficiently address the translation of systems biology to clinical & medical interventions (dominated by patient’s data heterogeneity and largely unstructured documents), ways to achieve synergy between Heuristic and Mathematical approaches can be effectively designed.

We apply first Heuristic modeling and then propose the outputs for Mathematical modeling when the system is correctly described.
The CADI™ Integration workflow

More details in the Full Presentation with CADI full Description, publications and the 10 CADI™ programs & POCS

Request our free Cochin Institute Training Session Presentation

- Nucleic acids
- Proteins
- etc...

Data acquisition
- Data analysis
- Experimental verification

Identified biological events

Database Searching

Production of working hypotheses

Hypothetic Physiological Mechanism

Biological Validation

Biological Modeling

Components Interactions maps

Destructive hypotheses testing
The CADI™ Integration & Modeling Process

This iterative process does three things:

- It largely resolves the coherence issues attached to the classical approach;
- It reveals hitherto unknown mechanisms/processes, and
- It allows the translation of systems biology to clinical & medical interventions.

More details in the Full Presentation with CADI full Description, publications and the 10 CADI™ programs & POCS
CADI™ Discovery Global validation Principle
exploiting Smart Data (contextualized, with patients based lines, related to mechanisms data)

CADI™ Discovery from bench to bed to real patient health processes

Information technologies
Data acquisition, Simulation, collaborative, data Storage, Big Data, Smart Data, Mobility

CADI™ Smart Data (contextualized, with patients based lines, related to mechanisms)
BMSystems Group at a glance

- Independent Private Company incorporated in 2004. 100% owned by its founders.
- Profitable since 2006, thanks to our recurrent clients.
- We only sell the results of the R&D programs, not our proprietary technologies.
- 100% biology driven company focused on discovery, and critical high impact decisions making
- A unique proprietary CADI™ Knowledge Database of mechanisms & interactions.
- Not domain-dependent, but information-dependent.
- Markets: Pharma, Cosmetics, Nutrition, Health Technologies, Connected health,
- Highly productive 24 vFTE* of which 9 vFTE on CADI™ Discovery programs only.
- Strong & long term strategic R&D collaborations (>100 people collaborating).
- Dual business model: Contractual or Collaborative R&D programs.
- External valorization of our collaborative R&D programs through out-licensing or spin-off.
- Outstanding internal pipeline of programs ready for collaborations.

14 successes independently validated by our clients/partners of which: 1 therapeutic spin-off and 1 exclusive out-license, 4 issued patents, 10 publications.

Potential competitors: Key Opinion Leaders, dominant thinking companies or pharma Systems Biology or bioinformatics teams argue they can do the same. We are always open for discussions & comparisons on success rates and outputs for patients.

The World’s first Mechanisms-Based Medicine Company
You have a R&D issue or a decision to make, we may have a solution for you.
Our 14 successes to date

Independently validated by our clients/partners

1. Mechanisms of pathogenesis & clinical progression of Creutzfeldt-Jakob Disease;
2. Mechanisms of anti-connexin agents for modulating the therapeutic effect of psychotropic and neurodegenerative drugs;
3. Cellular & metabolic mechanisms associated with chronic anxiety;
4. Mechanisms of N2O-mediated analgesia;
5. Anti-metastatic mechanisms of the RGD15 peptide;
6. Mechanisms of Ras-mediated breast cancer oncogenesis;
7. Mechanisms of breast cancer resistance to tamoxifen;
8. Regression mechanisms of the Müllerian duct;
9. Mechanisms of differential melanosome degradation;
10. Context-dependent functions of OA1 protein;
11. Context-dependent functions OCA2 protein;
12. Context-dependent functions SLC45A2 (MATP) protein;
13. Engineered bacteriophage banks and the control of multi-resistant pathogens;
14. Bioproduction and hemisynthesis of 18-methyl eicosanoic acid;
Our solutions to address Industry critical issues

- CADI™ Discovery’s *Integrated Descriptions of Biological Systems* is a valuable tool to generate novel hypotheses and/or challenge existing programs, key opinion leaders and experts recommendations spread all over the departments of the client’s company or partner’s structure.

We propose to R&D & Translational Medicine Executives, robust alternative decision-making to de-risk, save time, costs, and novel cost-effective diagnostics/therapies for their businesses.

1. GO-NO GO decision before product acquisition or for portfolio risk analysis.
2. GO-NO GO decision before next development phase.
3. R&D program Rescue for a program facing critical issues during its lifetime.
4. External R&D “B plan” program when the “A plan” cannot be rescued.
5. Exploratory Discovery program to discover novel causal mechanisms concepts.

You have a R&D issue or a decision to make, we may have a solution for you.
An experienced multidisciplinary founders’ team

Dr. François Iris (PhD), Chairman, CSO-CTO - Heuristic modeling specialist
French-New-Zealander. Geneticist, physiologist & molecular biologist. 40 years of experience in life sciences in academia and industry: Dept. of Medicine University of Otago, The Christchurch School of Medicine (NZ) Millennium Pharmaceuticals' (USA) collaborator of Nobel Laureate Prof. Jean Dausset. Inventor of CADITM and of new technologies in molecular biology. MRC Overseas fellow, Member of H.U.G.O., Wellcome Trust; etc..

Manuel Gea, C.E.O & VP R&D I. S. – Operational Research & business development specialist
30 years of experience in IT and life sciences. Scientific Engineering Degree from Ecole Centrale Paris. Various experiences R&D and business from consumer goods Industry to cosmetics, biotechnology & pharmaceutical companies: Colgate-Palmolive McKinsey, Boehringer Ingelheim, HemispherX Biopharma, Pherecyes-Pharma, BMSystems; etc..

Gérard Dine (MD, PhD), Chief Medical Officer - Physician, biologist
35 years of experience in clinical and medical research. Head of hospital’s Hematology Dept. Former President of the Institute for Sports Medicine; IRMES - Institute for Research in bioMedecine and Epidemiology of Sport, etc..

Paul-Henri Lampe, CIO & Systems Integration Director - Systems Integration specialist

Pablo Santamaria, IT & Internet Systems Director - Internet technologies specialist
30 years of experience in Internet technologies and life sciences. Scientific Engineering Degree from Ecole Centrale Paris, Founder and President of the computing firm Formitel, Glaxo Pharma (Evreux, France)
BMSystems’ outstanding POCs and our 2 first external outputs

**BMSystems/CEA collaborative research in neurodegenerative diseases.** World’s first in vivo validation of the mechanisms of Creutzfeldt-Jakob disease pathogenesis & progression. Two Awards (Bio IT World Best Practice Award 2009 and European Commission 2010).


**CEA/BMSystems collaborative research in CNS** (psychiatric and neurological disorders) led to the co-owned patent WO201029131 with a worldwide exclusive license to Theranexus CEA’s spin-off currently in Phase II.
5 ongoing BMSystems’ outstanding R&D programs

**Microbiota & Autism therapeutic H2020 program started with 14 M€ funding.** [GEMMA program](#) (Genome, Environment, Microbiome and Metabolome in Autism) gathers an international consortium of scientists to study the role of the gut microbiome in the development of Autism Spectrum Disorders (ASD).

**Etiology & Epigenetic and therapeutic evaluation for metabolic disorders program self funded.** [UMANG program](#) How does maternal nutrient restriction coupled with defective one-carbon metabolism alter the foetal development program, leading to enhanced predisposition to T2D in adolescence? Center of Excellence in Epigenetics IISER Pune India

**Diagnostic & Therapeutic evaluation program self funded.** The French Chronic Fatigue Syndrome Association decides to clinically evaluate the ME/CFS pathogenesis model produced by Bio-Modeling.

**Therapeutic evaluation program self funded. Parkinson’s disease and metabolic syndrome.** The program led to a combinatorial therapeutic approach utilizing two molecules that had long been on the market, neither of which has any known toxicity or undesirable effects. Evaluation status: Discussion with confidential partners

**Causal metabolic mechanisms of Alzheimer Disease (AD) model was produced by Bio-Modeling System in 2017-2018.** The model in its current state is able to produce biomarkers that could probably predict or increase alertness for identifying AD at its very early stages of progression. [Discover the 14 key components explained](#)
Our collaborative R&D programs & their outputs
This list excludes our contractual research programs with our clients


Max Planck Institute (Munich): Project “Chronic Anxiety”.
Successfully completed; 3 publications & a Reference Book “Biomarkers for Psychiatric disorders” chapter 19.

INSERM: 3 Projects “Tumoral Progression”; “Therapeutic Resistance”; “RGD 15 & Metastasis”.
All 3 successfully completed, 3 publications.

CNRS: Project “Müllerian Regression” Tissue differentiation
Successfully completed, 1 publication.

Foundation FondaMental: Project “Bipolar Disorders & Schizophrenia”. Immuno-inflammatory hypothesis. On going, 1 publication pending.

L’OREAL Arkema, Rhodia/Solvay ARD: “Synthons” Government funded feasibility Program at IAR cluster Industrial Biotech
Feasibility study Completed 16 molecules evaluated, 2 strains built, 1 program with 1 patent (industrial partner only)
Skin Homeostasis: Reference book “Computational Biophysics of Skin” chapter 15 with Dr. Querleux (L’Oreal)

Centre of excellence in Epigenetics IISER Pune India: Project “Etiology & Epigenetic for metabolic disorders” Etiology & Epigenetic for metabolic disorders, on going 1 publication pending
BMSystems’ R&D programs pipeline
External valorization of our collaborative R&D programs through out-licensing or spin-off

<table>
<thead>
<tr>
<th>Program Domains</th>
<th>Partners</th>
<th>CADI™ compliance</th>
<th>CADI™ vers. 0</th>
<th>Ind. Valid.</th>
<th>Secret or Patent or Co-Patent/Publi.</th>
<th>First Proof of Concept (POC)</th>
<th>Mid scale or preclin. P.O.C.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infection-Immunology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Microbiotas (skin, lung, gut, etc)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurology/Psychiatry (CNS-PNS)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabolism</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dermatology/Cometics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BioProcesses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

© BMSystems - www.bmsystems.net
# BMSystems’ R&D programs pipeline (details)

<table>
<thead>
<tr>
<th>Program Name</th>
<th>Validation / Business Partner(s)</th>
<th>CADI™ compliance</th>
<th>CADI™ vers. 0</th>
<th>Ind. Valid.</th>
<th>Secret or Patent or Co-Patent/Publi.</th>
<th>First Proof of Concept (POC)</th>
<th>Mid scale or Predclin. P.O.C.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nano-Bioagents</td>
<td>Pherectomy</td>
<td>Ind. Valid.</td>
<td>Secret or Patent or Co-Patent/Publi.</td>
<td>First Proof of Concept (POC)</td>
<td>Mid scale or Predclin. P.O.C.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TAPE (protein improvement)</td>
<td>Open</td>
<td>CADI™ vers. 0</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic Fatigue Syndrome</td>
<td>Open</td>
<td>CADI™ vers. 0</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ebola virus ecology</td>
<td>Open</td>
<td>CADI™ vers. 0</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis C</td>
<td>Open</td>
<td>CADI™ vers. 0</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Auto-immune global concept</td>
<td>Open</td>
<td>Start</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuberculosis &amp; Autism H2020 program 14 M€ funded</td>
<td>H2020</td>
<td>Open</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Microbiota ecology, physiology &amp; metabolic mechanisms</td>
<td>Open</td>
<td>Start</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Microbiota &amp; inflammation</td>
<td>Open</td>
<td>Open</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creutzfeldt-Jakob disease’s mechanisms</td>
<td>CEA Life Sciences</td>
<td>Open</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cellular &amp; metabolic mechanisms associated with chronic anxiety</td>
<td>Max Planck Munich</td>
<td>Open</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psychiatric Disorders therapeutic strategy</td>
<td>Confidential</td>
<td>Open</td>
<td>Confidential</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alzheimer’s Disease Causal Mechanisms</td>
<td>Open</td>
<td>Open</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parkinson’s Disease Therapy</td>
<td>Open</td>
<td>Open</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psychiatric inflammatory mechanisms</td>
<td>Open</td>
<td>Open</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fibromyalgia, facial pain</td>
<td>FondaMental Foundation</td>
<td>Open</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain (Central/Peripheral)</td>
<td>Open</td>
<td>Produced</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Migraine Mechanisms</td>
<td>Open</td>
<td>Produced</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiple Sclerosis Mechanisms</td>
<td>Open</td>
<td>Produced</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Etiology &amp; Epigenetic in diabetes type 2</td>
<td>IISER Pune</td>
<td>Open</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabolic Disorders Therapy</td>
<td>Open</td>
<td>Open</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypercholesteremia Mechanisms</td>
<td>Open</td>
<td>Open</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New global concept for Diabetes type 1</td>
<td>Open</td>
<td>Open</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabolic Syndrome</td>
<td>Open</td>
<td>Open</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast cancer-Hras</td>
<td>INSEM</td>
<td>Produced</td>
<td>Produced</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tamoxifen resistance</td>
<td>INSEM</td>
<td>Produced</td>
<td>Produced</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Specific Metastasis control</td>
<td>INSEM</td>
<td>Produced</td>
<td>Produced</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Encysting Tumour Therapy</td>
<td>CNRS</td>
<td>Produced</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Müllerian regression Mechanisms</td>
<td>CNRS</td>
<td>Produced</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adipocytes growth control</td>
<td>CNRS</td>
<td>Produced</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin pigmentation Mechanisms</td>
<td>Open</td>
<td>Open</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin pigmentation Modulation</td>
<td>Open</td>
<td>Open</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin Contact Allergy Mechanisms</td>
<td>Open</td>
<td>Open</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin aging Mechanisms</td>
<td>Open</td>
<td>Open</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Modulation of skin hydration</td>
<td>Open</td>
<td>Open</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Modulation of the lipid constituents of the skin barrier</td>
<td>Open</td>
<td>Open</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Novel Hair Loss Mechanisms</td>
<td>Open</td>
<td>Open</td>
<td>Open</td>
<td>Produced</td>
<td>Produced</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program Synthons</td>
<td>ARD-IBT-L’Oréal</td>
<td>Validated</td>
<td>Validated</td>
<td>Validated</td>
<td>Validated</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human Glycosylation with Yeast</td>
<td>Open</td>
<td>Validated</td>
<td>Validated</td>
<td>Validated</td>
<td>Validated</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>